While GFAP levels in blood and CSF are associated and correlated to amyloid pathology [99] and related to clinical disease severity [100], GFAP might be a potential biomarker of other types of dementia because astrocytes are not the foremost cell type specific to AD pathophysiology. This evidence concerns the gene GFAP and dementia.